clinicaltrials.gov· University Health Network, Toronto · ClinicalTrials.gov·· 2 hours agoPickScore35
SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer
In brief
NCT07883005 plans to enroll 288 head and neck cancer patients in a Phase III randomized controlled trial evaluating whether SALI-10 can reduce the risk of radiation-related major adverse dental events (MADE). Patients will be randomized to standard of care or standard of care plus SALI-10 lozenges; MADE is defined as tooth failure and/or grade 2 or higher jaw osteoradionecrosis. The trial is not yet recruiting and is planned to start on 2026-11-01.
Why it matters
Newly registered Phase III trial tests a probiotic against radiotherapy dental toxicity.
Source: clinicaltrials.gov · clinicaltrials.gov